Treatment Decisions in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Changing Treatment Paradigms in Chronic Lymphocytic Leukemia
Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of BTKi and BCL-2 inhibitors as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has significantly transformed the treatment landscape of relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
The Evolving Landscape in CLL/SLL: Best Practice Clinical Applications of Current Evidence and New Guideline Recommendations
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
There is a continuing need to educate clinicians about the emerging treatment options as this will aid in the successful implementation of more effective treatment options in routine clinical setting.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies
Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.
Category
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation